These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 4014238)

  • 1. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 3. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 5. If it's regulated like a duck ... uncertainties in implementing the patent exceptions of the Drug Price Competition and Patent Term Restoration Act.
    Bloch DJ
    Food Drug Law J; 1999; 54(1):111-26. PubMed ID: 11758554
    [No Abstract]   [Full Text] [Related]  

  • 6. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 11. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status of generic substitution: problematic drug classes reviewed.
    Ross MB
    Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projecting future drug expenditures--1992.
    Ensor PA
    Am J Hosp Pharm; 1992 Jan; 49(1):140-5. PubMed ID: 1570858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations.
    Knoben JE; Scott GR; Tonelli RJ
    Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Projecting future drug expenditures--1993.
    Santell JP
    Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.
    Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Beyer A; Visaria J
    Food Drug Law J; 2009; 64(1):171-81. PubMed ID: 19998745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
    Rodriguez-Monguio R; Seoane-Vazquez E
    AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncharted territories of the patent-restoration due-diligence challenge.
    Gaudry KS
    Food Drug Law J; 2011; 66(1):121-38, iii. PubMed ID: 24505850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projecting future drug expenditures--1994.
    Santell JP
    Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.